• 1
    Jensen RT. Pancreatic endocrine tumors: recent advances. Ann Oncol 1999; 10( suppl 4): S170S176.
  • 2
    Gumbs AA, Moore PS, Falconi M, Bassi C, Beghelli S, Modlin I, Scarpa A. Review of the clinical, histological, and molecular aspect of pancreatic endocrine neoplasms. J Surg Oncol 2002; 81: 4553.
  • 3
    Corleto VD, Delle Fave G, Jensen RT. Molecular insights into gastrointestinal neuro-endocrine tumors: importance and recent advances. Dig Liver Dis 2002; 34: 66880.
  • 4
    Peghini PL, Iwamoto M, Raffeld M, Chen Y-J, Goebel SU, Serrano J, Jensen RT. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 2002; 8: 227385.
  • 5
    Nikiforava MN, Nikiforov YE, Biddinger P, Gnepp DR, Grosembacher LA, Wajchenberg BL, Fagin JA, Cohen RM. Frequent loss of heterozygosity at chromosome 3p14.2-3p21 in human pancreatic islet cell tumours. Clin Endocrinol (Oxf.) 1999; 51: 2733.
  • 6
    Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G, Pesci A, Baron A, Lissandrini D, Rindi G, Grigolato P, Pederzoli P, et al. High resolution allelotype of nonfunctional endocrine pancreatic tumors: identification of two molecular subgroups with clinical implications. Cancer Res 2001; 61: 28592.
  • 7
    Chen Y-J, Vortmeyer AO, Zhuang Z, Gibril F, Jensen RT. X-chromosome loss of heterozygosity frequently occurs in gastrinomas and is correlated with aggressive tumor growth. Cancer 2004; 100: 137987.
  • 8
    Missiaglia E, Moore PS, Williamson J, Lemoine NR, Falconi M, Zamboni G, Scarpa A. Sex chromosome anomalies in pancreatic endocrine tumors. Int J Cancer 2002; 98: 5328.
  • 9
    Pizzi S, D'Adda T, Azzoni C, Rindi G, Grigolato P, Pasquali C, Corleto VD, Della Fave G, Bordi C. Malignancy-associated allelic losses on the X chromosome in foregut but not in midgut endocrine tumours. J Pathol 2002; 196: 4017.
  • 10
    Speel EJM, Scheidweiler AF, Zhao J, Matter C, Saremaslani P, Roth J, Heitz PU, Komminoth P. Genetic evidence for early divergence of small functioning and nonfunctioning endocrine tumors: gain of 9Q34 is an early event in insulinomas. Cancer Res 2001; 61: 518692.
  • 11
    Barghorn A, Speel EJ, Farspour B, Saremaslani P, Schmid S, Perren A, Roth J, Heitz PU, Komminoth P. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol 2001; 158: 190311.
  • 12
    Hessman O, Skogseid B, Westin G, Akerstrom G. Multiple allelic deletions and intratumoral genetic heterogeneity in MEN1 pancreatic tumors. J Clin Endocrinol Metab 2001; 86: 135561.
  • 13
    Lubomierski N, Kersting M, Bert T, Muench K, Wulbrand U, Schuermann M, Bartsch D, Simon B. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors. Cancer Res 2001; 61: 590510.
  • 14
    Chung DC, Brown SB, Graeme-Cook F, Tillotson LG, Warshaw AL, Jensen RT, Arnold A. Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res 1998; 58: 370611.
  • 15
    Guo S, Arora C, Shimoide AT, Sawicki MP. Frequent deletion of chromosome 3 in malignant sporadic pancreatic endocrine tumors. Mol Cell Endocrinol 2002; 190: 10914.
  • 16
    Serrano J, Gorbel SU, Peghini PL, Lubensky IA, Gibril F, Jensen RT. Alterations in the p16 INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 2000; 85: 414656.
  • 17
    Bartsch DK, Kersting M, Wild A, Ramaswamy A, Gerdes B, Schuermann M, Simon B, Rothmund M. Low frequency of p16 (INK4a) alterations in insulinomas. Digestion 2000; 62: 1717.
  • 18
    Perren A, Saremaslani P, Schmid S, Bonvin C, Locher T, Roth J, Heitz PU, Komminoth P. DPC4/Smad4: no mutations, rare allelic imbalances, and retained protein expression in pancreatic endocrine tumors. Diagn Mol Pathol 2003; 12: 1816.
  • 19
    Bartsch DK, Hahn SA, Danichevski KD, Ramaswamy A, Bastian D, Galedhari H, Barth P, Schmiegel W, Simon B, Rothmund M. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene 1999; 18: 236771.
  • 20
    Lee CS. Lack of p53 immunoreactivity in pancreatic endocrine tumors. Pathology 1996; 28: 13941.
  • 21
    Lam KY, Lo CY. Role of p53 tumor suppressor gene in pancreatic endocrine tumors of Chinese patients. Am J Gastroenterol 1998; 93: 12325.
    Direct Link:
  • 22
    Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M, Bassi C, Lemoine NR, Scarpa A. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 2001; 84: 25362.
  • 23
    Agarwal SK, Burns AL, Sukhodolet KE, Kennedy PA, Obungu VH, Hickman AB, Mullendore ME, Whitten I, Skarulis MC, Simonds WF, Mateo C, Crabtree JS, et al. Molecular pathology of the MEN1 gene. Ann NY Acad Sci 2004; 1014: 18998.
  • 24
    Debelenko LV, Zhuang ZP, Emmert-Buck MR, Chandrasekharappa SC, Manickam P, Guru SC, Marx SJ, Skarulis MC, Spiegel AM, Collins FS, Jensen RT, Liotta LA, et al. Allelic deletions on chromosome 11q13 in MEN1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 1997; 57: 223843.
  • 25
    Zhuang Z, Vortmeyer AO, Park S, Huang S, Pham TA, Wang C, Park WS, Agarwal SK, Debelenko LV, Kester M, Guru SC, Manickam P, et al. Somatic mutation of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997; 57: 46826.
  • 26
    Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, Marx SJ. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001; 12: 1738.
  • 27
    Guo SS, Sawicki MP. Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. Mol Endocrinol 2001; 15: 165364.
  • 28
    Cavallari I, D'Agastino DM, Ferro T, Rosato A, Barzon L, Pasquali C, Fogar P, Theodoropoulou M, Esposito G, Boscaro M, Pagotto U, Tebaldi E, et al. In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells. J Clin Endocrinol Metab 2003; 88: 3893901.
  • 29
    Cupisti K, Hoppner W, Dotzenrath C, Simon D, Berndt I, Roher HD, Goretzki PE. Lack of MEN1 gene mutations in 27 sporadic insulinomas. Eur J Clin Invest 2000; 30: 3259.
  • 30
    Guo SS, Wu AY, Sawicki MP. Deletion of chromosome 1, but not mutation of MEN-1, predicts prognosis in sporadic pancreatic endocrine tumors. World J Surg 2002; 26: 8437.
  • 31
    Gortz B, Roth J, Krahenmann A, de Krijger RR, Muletta-Feurer S, Rutimann K, Saremaslani P, Speel EJM, Heitz PU, Komminoth P. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 1999; 154: 42936.
  • 32
    Hessman O, Lindberg D, Einarsson A, Lillhager P, Carling T, Grimelius L, Eriksson B, Akerstrom G, Westin G, Skogseid B. Genetic alteration on 3p, 11q13, and 18q in nonfamilial and MEN1-associated pancreatic endocrine tumors. Genes Chromosomes Cancer 1999; 26: 25864.
  • 33
    Zhao Y, Wang X, Yang B, Xiao Y, Cai L, Zhong S, Zhu Y. Pancreatic insulinomas: experience in 220 patients. Zhonghua Wai Ke Za Zhi 2000; 38: 1013 (Chinese).
  • 34
    Chen Y-J, Vortmeyer AO, Zhuang Z, Huang S, Jensen RT. Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance. Cancer Res 2003; 63: 81723.
  • 35
    Ebrahimi SA, Wang EH, Wu A, Schreck RR, Passaro EJr, Sawicki MP. Deletion of chromosome 1 predicts prognosis in pancreatic endocrine tumors. Cancer Res 1999; 59: 3115.
  • 36
    Speel EJM, Richter J, Moch H, Egenter C, Saremaslani P, Rutimann K, Zhao J, Barghorn A, Roth J, Heitz PU, Komminoth P. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 1999; 155: 178794.
  • 37
    Yu F, Jensen RT, Lubensky IA, Mahlamaki EH, Zheng Y-L, Herr AM, Ferrin LJ. Survey of genetic alterations in gastrinomas. Cancer Res 2000; 60: 553642.
  • 38
    Grant CS. Surgical aspects of hyperinsulinemic hypoglycemia. Endocrinol Metab Clin North Am 1999; 28: 53354.
  • 39
    Jiang W-J, Liu T-H, Chen J, Gao J, Wu S-F, Chen Y-J. Frequent loss of heterozygosity at MEN1 gene and chromosome 22q in insulinomas and its significance. Natl Med J China 2004; 84: 17059 (Chinese, English abstract).
  • 40
    Leotlela PD, Jauchl A, Holtgreve-Grezl H, Thakker RV. Genetics of neuroendocrine and carcinoid tumors. Endocr Related Cancer 2003; 10: 43750.
  • 41
    House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 2003; 238: 42331.
  • 42
    House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. Surgery 2003; 134: 9028.
  • 43
    Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 2003; 22: 92434.
  • 44
    Wild A, Ramaswamy A, Langer P, Celik I, Fendrich V, Chaloupka B, Simon B, Bartsch DK. Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. J Clin Endocrinol Metab 2003; 88: 136773.
  • 45
    Beghelli S, Pelosi G, Zamboni G, Falconi M, Iacono C, Bordi C, Scarpa A. Pancreatic endocrine tumors: evidence for a tumor suppressor pathogenesis and for a tumor suppressor gene on chromosome 17p. J Pathol 1998; 186: 4150.
  • 46
    Moore PS, Missiaglia E, Antonello D, Zamo A, Zamboni G, Corleto V, Falconi M, Scarpa A. Role of disease-cause genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes Chromosomes Cancer 2001; 32: 17781.
  • 47
    Wild A, Langer P, Ramaswamy A, Chaloupka B, Bartsch DK. A novel insulinoma tumor suppressor gene locus on chromosome 22q with potential prognostic implications. J Clin Endocrinol Metab 2001; 86: 57827.
  • 48
    Haven CJ, van Puijenbroek M, Karperien M, Fleuren GJ, Morreau H. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol 2004; 202: 8694.
  • 49
    Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Association of allelic loss on 1q, 4p, 7q, 9p, 9q, and 16q with postoperative death in papillary thyroid carcinoma. Clin Cancer Res 2000; 6: 181925.
  • 50
    Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes Chromosomes Cancer 2000; 27: 24451.
  • 51
    Dwight T, Twigg S, Delbridge L, Wong FK, Farnebo F, Richardson AL, Nelson A, Zedenius J, Philips J, Larsson C, Teh BT, Robinson B. Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q 13. Clin Endocrinol 2000; 53: 8592.
  • 52
    Teh BT, Farnebo F, Twigg S, Hoog A, Kytola S, Korpi-Hyovalti E, Wong FK, Nordenstrom J, Grimelius L, Sandelin K, Robinson B, Farnebo LO, et al. Familial isolated heperparathyroidism maps to the heperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. J Clin Endocrinol Metab 1998; 83: 211420.
  • 53
    Emmert-Buck MR, Lubensky IA, Dong Q, Manickam P, Guru SC, Kester MB, Olufemi S-E, Agarwal SK, Burns AL, Spiegel AM, Collins FS, Marx SJ, et al. Localization of the multiple endocrine neoplasia type I (MEN1) gene based on tumor loss heterozygosity analysis. Cancer Res 1997; 57: 18558.
  • 54
    Stumpf E, Aalto Y, Hoog A, Kjellman M, Otonkoski T, Knuutila S, Andersson LC. Chromosomal alterations in human pancreatic endocrine tumors. Genes Chromosomes Cancer 2000; 29: 837.
  • 55
    Hobbs MR, Pole AR, Pidwirn GN, Rosen IB, Zarbo RJ, Coon H, Heath H, Leppert M, Jackson CE. Hyperparathyroidism-jaw tumor syndrome: the HRPT2 locus is within a 0.7-cM region on chromosome 1q. Am J Hum Genet 1999; 64: 51825.
  • 56
    Sauane M, Gopalkrishnan RV, Lebedeva I, Mei MX, Sarkar D, Su ZZ, Kang DC, Dent P, Pestka S, Fisher PB. Mda-7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathway. J Cell Physiol 2003; 196: 33445.
  • 57
    Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su ZZ, Lebedeva IV, Kang DC, Jiang H, Lin JJ, Alexandre D, Chen Y, Vozhilla N, et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 2001; 20: 705163.
  • 58
    Fujiuchi N, Aglipay JA, Ohtsuka, T, Maehara N, Sahin F, Su GH, Lee SW, Ouchi T. Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation. J Biol Chem 2004; 279: 2033944.
  • 59
    DeYoung KL, Ray ME, Su YA, Anzick SL, Johnstone RW, Trapani JA, Meltzer PS, Trent JM. Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene 1997; 15: 4537.